Latest Period
Q1 2026
Security Snapshot
TriSalus Life Sciences, Inc. - Common Stock, $0.01 par value (TLSI) Institutional Ownership
CUSIP: 89680M101
13F Institutional Holders and Ownership History from Q3 2023 to Q1 2026
Institutions Reporting
77
Shares (Excl. Options)
20,313,302
Price
$4.00
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.01 par value
- Symbol
- TLSI on Nasdaq
- Shares outstanding
- 61,418,480
- Price per share
- $4.53
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 20,313,302
- Total reported value
- $81,251,361
- % of total 13F portfolios
- 0%
- Share change
- +9,107,663
- Value change
- +$32,766,003
- Number of holders
- 77
- Price from insider filings
- $4.53
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- TLSI - TriSalus Life Sciences, Inc. - Common Stock, $0.01 par value is tracked under CUSIP 89680M101.
- 77 institutions reported positions in Q1 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 62 to 77 between Q4 2025 and Q1 2026.
- Reported value moved from $79,628,749 to $81,251,361.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 77 institutions filings for Q1 2026.
Investment Quick Answers
What is CUSIP 89680M101?
CUSIP 89680M101 identifies TLSI - TriSalus Life Sciences, Inc. - Common Stock, $0.01 par value in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q1 2026 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 89680M101:
Significant Owners of TriSalus Life Sciences, Inc. - Common Stock, $0.01 par value (TLSI) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Frankenius Equity AB | 14% | -31% | $34,179,868 | +$1,257,864 | 6,989,748 | +3.8% | Frankenius Equity AB | 31 Jul 2025 |
| First Light Asset Management, LLC | 8.8% | $22,463,809 | 5,374,117 | First Light Asset Management, LLC | 31 Mar 2026 | |||
| Utmost Group Plc | 5.7% | -15% | $14,644,149 | +$493,867 | 3,503,385 | +3.5% | Utmost Group PLC | 31 Mar 2026 |
| Wahlstrom Mats | 6% | -33% | $14,610,738 | +$931,271 | 2,987,881 | +6.8% | Mats Wahlstrom | 31 Jul 2025 |
| Nantahala Capital Management, LLC | 4.1% | -24% | $9,487,139 | +$187,139 | 2,040,245 | +2% | Nantahala Capital Management, LLC | 30 Sep 2025 |
As of 31 Mar 2026, 77 institutional investors reported holding 20,313,302 shares of TriSalus Life Sciences, Inc. - Common Stock, $0.01 par value (TLSI). This represents 33% of the company’s total 61,418,480 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of TriSalus Life Sciences, Inc. - Common Stock, $0.01 par value (TLSI) together control 32% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| First Light Asset Management, LLC | 8.2% | 5,066,827 | 1.8% | $20,267,308 | |
| AWM Investment Company, Inc. | 3.4% | 2,079,105 | +67% | 0.92% | $8,316,420 |
| Nantahala Capital Management, LLC | 3.4% | 2,070,827 | 0% | 0.52% | $8,283,308 |
| BlackRock, Inc. | 2.4% | 1,499,547 | -2.3% | 0% | $5,998,188 |
| WASATCH ADVISORS LP | 2.3% | 1,437,960 | 0.04% | $5,751,840 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.2% | 1,347,036 | 0% | 0% | $5,388,144 |
| GILDER GAGNON HOWE & CO LLC | 1.4% | 888,515 | -9.2% | 0.04% | $3,554,060 |
| Cerity Partners LLC | 1.3% | 787,272 | 0% | $3,149,088 | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.3% | 777,094 | +3.4% | 0% | $3,109,525 |
| THOMPSON SIEGEL & WALMSLEY LLC | 0.95% | 583,574 | 0.04% | $2,334,000 | |
| KENNEDY CAPITAL MANAGEMENT LLC | 0.79% | 485,242 | 0.04% | $1,940,968 | |
| MORGAN STANLEY | 0.64% | 393,909 | +7.8% | 0% | $1,575,636 |
| STATE STREET CORP | 0.53% | 328,020 | +24% | 0% | $1,312,080 |
| PERKINS CAPITAL MANAGEMENT INC | 0.37% | 230,101 | 0.86% | $920,404 | |
| NORTHERN TRUST CORP | 0.36% | 221,473 | -0.34% | 0% | $885,892 |
| VANGUARD FIDUCIARY TRUST CO | 0.36% | 218,352 | 0% | 0% | $873,408 |
| ROYCE & ASSOCIATES LP | 0.33% | 200,060 | 0.01% | $800,240 | |
| Apis Capital Advisors, LLC | 0.29% | 180,000 | 0.11% | $720,000 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.27% | 164,858 | 0% | 0% | $659,432 |
| WHITE PINE CAPITAL LLC | 0.27% | 163,810 | +180% | 0.18% | $655,240 |
| Corient Private Wealth LLC | 0.15% | 91,000 | 0% | $364,000 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.14% | 84,137 | -16% | 0% | $336,548 |
| UBS Group AG | 0.13% | 79,552 | +1445% | 0% | $318,208 |
| GOLDMAN SACHS GROUP INC | 0.12% | 75,049 | +14% | 0% | $300,196 |
| CWA Asset Management Group, LLC | 0.12% | 72,000 | 0% | 0.01% | $288,000 |
Institutional Holders of TriSalus Life Sciences, Inc. - Common Stock, $0.01 par value (TLSI) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 20,313,302 | $81,251,361 | +$32,766,003 | $4.00 | 77 |
| 2025 Q4 | 11,407,711 | $79,628,749 | +$12,128,066 | $6.98 | 62 |
| 2025 Q3 | 9,563,230 | $44,470,060 | +$5,042,569 | $4.65 | 54 |
| 2025 Q2 | 8,470,104 | $46,161,422 | +$30,072,898 | $5.45 | 46 |
| 2025 Q1 | 2,947,768 | $16,271,736 | +$3,567,159 | $5.52 | 33 |
| 2024 Q4 | 2,345,660 | $11,752,144 | +$904,681 | $5.01 | 28 |
| 2024 Q3 | 2,171,190 | $10,009,408 | +$2,041,090 | $4.61 | 31 |
| 2024 Q2 | 1,617,489 | $8,929,169 | +$3,605,411 | $5.52 | 26 |
| 2024 Q1 | 925,707 | $9,026,910 | +$2,616,406 | $9.75 | 24 |
| 2023 Q4 | 679,602 | $5,741,892 | +$4,363,853 | $8.45 | 19 |
| 2023 Q3 | 136,575 | $699,263 | +$699,263 | $5.12 | 9 |